Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Chapter 18 - Post-mortem Studies of the Brain Cannabinoid System in Schizophrenia

  • from Part VI - Cannabinoids and Schizophrenia: Aetiopathology and Treatment Implications
  • Edited by Deepak Cyril D'Souza, Staff Psychiatrist, VA Connecticut Healthcare System; Professor of Psychiatry, Yale University School of Medicine, David Castle, University of Tasmania, Australia, Sir Robin Murray, Honorary Consultant Psychiatrist, Psychosis Service at the South London and Maudsley NHS Trust; Professor of Psychiatric Research at the Institute of Psychiatry
  • Book:
    Marijuana and Madness
    Published online:
    12 May 2023
    Print publication:
    01 June 2023, pp 178-188

  • Summary

    Post-mortem human brain tissue provides a valuable resource to probe the mechanisms underlying associations between cannabis and schizophrenia and how the endocannabinoid system may be dysregulated in the disorder. Although the endocannabinoid system has been variously examined, the majority of studies have focused on its stable components, in particular, the cannabinoid CB1 receptor in brain regions relevant to schizophrenia. Its widespread distribution throughout the human CNS and localization to GABA containing inhibitory interneurons and excitatory glutamate pyramidal neurons add relevance to its potential role in schizophrenia. The weight of evidence supports an increase in cannabinoid CB1 receptor density in prefrontal cortical and striatal regions without a commensurate increase in mRNA expression and a possible increase in the endogenous ligand, 2-arachidonoylglycerol. These changes in tissue from people without a history of cannabis use suggests the endocannabinoid system may be implicated in schizophrenia, although potential confounds of treatment and other factors need to be considered.